Cokgor, I., Akabani, G., Brown, M. T., Friedman, A. H., Coleman, R. E., Friedman, H. S., … Bigner, D. D. (1998). Results of a phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with ¹³¹I-labeled antitenascin monoclonal antibody 81C6 via surgically created resection cavities. In NEUROLOGY (Vol. 50, pp. A354–A354).

Cokgor, I., G. Akabani, M. T. Brown, A. H. Friedman, R. E. Coleman, H. S. Friedman, W. L. Thorstad, et al. “Results of a phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with ¹³¹I-labeled antitenascin monoclonal antibody 81C6 via surgically created resection cavities.” In NEUROLOGY, 50:A354–A354, 1998.

Cokgor I, Akabani G, Brown MT, Friedman AH, Coleman RE, Friedman HS, et al. Results of a phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with ¹³¹I-labeled antitenascin monoclonal antibody 81C6 via surgically created resection cavities. In: NEUROLOGY. 1998. p. A354–A354.

Cokgor, I., et al. “Results of a phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with ¹³¹I-labeled antitenascin monoclonal antibody 81C6 via surgically created resection cavities.” NEUROLOGY, vol. 50, no. 4, 1998, pp. A354–A354.

Cokgor I, Akabani G, Brown MT, Friedman AH, Coleman RE, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, Zalutsky MR, Bigner DD. Results of a phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with ¹³¹I-labeled antitenascin monoclonal antibody 81C6 via surgically created resection cavities. NEUROLOGY. 1998. p. A354–A354.